#tirzepatide

#tirzepatide

Zepbound's new self-dosing option provides significant cost savings for patients willing to administer their own injections.

Zepbound gains FDA approval for treating obstructive sleep apnea, marking a breakthrough in weight-loss medication benefits.

Eli Lilly is significantly reducing the price of Zepbound to $399-$549 to combat counterfeits and enhance patient access.

Eli Lilly is suing telehealth companies for selling illegal copies of its drug Zepbound, which uses the active ingredient tirzepatide.

FDA allowed compounding pharmacies a grace period to cease production post-drug shortage, but some continue to sell modified tirzepatide products.

Compounding pharmacies are suing the FDA to continue producing tirzepatide imitations despite the drug's supply improving.

The FDA announced that the tirzepatide shortage has been resolved, impacting compounding pharmacies' operations.

Obesity treatments are transforming patients' relationship with food but compounding alternatives to popular drugs face restrictions.

FDA's declaration ends availability of compounded tirzepatide, causing distress among patients who rely on it.

The ongoing demand for GLP-1s has resulted in a significant shortage and legal dispute regarding alternative compounding pharmacies.

Pivotal Peptides is allegedly operating in a way that poses significant risks to patient safety, utilizing coded language for product orders.

The FDA has resolved the tirzepatide shortage, improving access to brand-name drugs but disrupting the compounded medication market.

Semaglutide and tirzepatide mimic GLP-1 to control blood sugar levels and induce feelings of fullness, potentially offering benefits for kidney protection and reducing inflammation in conditions like dementia.

Drugs like Ozempic and Mounjaro are linked to severe eye conditions, particularly NAION, causing increasing concern among healthcare providers.

People with obesity now have a choice between semaglutide and tirzepatide for weight loss, but deciding which to take is complex.

Mounjaro, a leading weight loss drug, will be rolled out on the NHS prioritizing patients with significant health needs over 12 years.

Mounjaro is an effective treatment option for obesity and type 2 diabetes, approved for use with diet and physical activity.

Tirzepatide's dual receptor activation may contribute to its efficacy in weight loss, while GIP's role is not fully understood yet.

Tirzepatide may reduce diabetes risk by 94% and help in weight loss for high-risk individuals.